Welcome to the Wet AMD & DME Drug Development Summit
The second edition of the industry-led Wet AMD & DME Drug Development Summit took place in Boston this year to give comprehensive insight into the current and emerging angiogenesis- inflammatory-directed and anti-fibrotic drug development programs for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and diabetic macular edema (DME).
Attendees were able to network in person and learn from senior leaders of discovery, translational sciences, and clinical development from the likes of Roche, Genentech, Novartis, Apellis, Outlook Therapeutics and more, to address the specific challenges for the biopharmaceutical and biotechnology in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care in this vast ophthalmology indication.
The conference included 3 jam-packed days including two workshops exploring the optimization of administration techniques and viral and non-viral vectors to deliver safe & durable anti-angiogenic therapies to the eye and developing preclinical and translational models to predict human disease and efficacy of a drug.
Expert Speakers Included:
Vitreoretinal Surgeon & Clinical Investigator
New England Retina Associates
Chief Medical Officer
Director External Innovation and Translational Biomarkers
Novartis Institutes for Biomedical Research, Department of Ophthalmology
Centre for Eye Research Australia
2022 Sponsoring Partners:
Snapshot of Attendees at the 2nd Wet AMD & DME Drug Development Summit:
Feedback from the Wet AMD & DME Drug Development Summit:
“Outstanding program with diverse and salient presentations regarding advances in the treatment of Wet AMD and DME”
CEO, ForwardVue Pharma
“Comprehensive and informative”
Chief Medical Officer, Chair-Cell Biology of the Faculty of Science, Radboud University Nijmegen